Design and Synthesis of Novel Anticancer Peptide Nanoparticles
Abstract
Cancer has now become a common disease affecting human health. Existing cancer treatment drugs can no longer meet the growing needs of cancer patients, and the emergence of anticancer drug resistance has exacerbated this phenomenon. By designing and synthesizing new anticancer peptide nanoparticles and studying their anticancer effects, new strategies for cancer treatment may be obtained. Novel anticancer peptides are synthesized by adding basic amino acids and solid-phase synthesis technology, and their structural information is determined by mass spectrometry. Nanoparticles of anticancer peptide were synthesized by nano-self-assembly technology. Two novel anticancer peptides exhibited anticancer activity, one of which was assembled into nanoparticles. The theoretical isoelectric points of the modified SZG3 and SZG5 are all greater than physiological pH, and will be positively charged under physiological conditions. The estimated half-life of SZG3 and SZG5 is significantly extended (30h), which is beneficial to increase the efficacy and reduce toxic and side effects. SZG3 and SZG5 have a good inhibitory effect on tumor cells and have low toxicity to normal cells.
Keywords: anticancer peptide, study, design, cancer, nanoparticles
Keywords:
anticancer peptide, study, study, design, cancer, nanoparticlesDOI
https://doi.org/10.22270/jddt.v10i4.4156References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769-92.
Yamaguchi Y, Ouchi Y. Antimicrobial peptide defensin: identification of novel isoforms and the characterization of their physiological roles and their significance in the pathogenesis of diseases. Proceedings of the Japan Academy, Series B. 2012;88(4):152-66.
Scocchi M, Tossi A, Gennaro R. Proline-rich antimicrobial peptides: converging to a non-lytic mechanism of action. Cellular and Molecular Life Sciences. 2011;68(13):2317-30.
Yedery RD, Jerse AE. Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections. Antibiotics. 2015;4(1):44-61.
Malvisi M, Stuknytė M, Magro G, Minozzi G, Giardini A, De Noni I, et al. Antibacterial activity and immunomodulatory effects on a bovine mammary epithelial cell line exerted by nisin A-producing Lactococcus lactis strains. Journal of dairy science. 2016;99(3):2288-96.
Hu E, Wang D, Chen J, Tao X. Novel cyclotides from Hedyotis diffusa induce apoptosis and inhibit proliferation and migration of prostate cancer cells. International journal of clinical and experimental medicine. 2015;8(3):4059-65.
Du Q, Hou X, Wang L, Zhang Y, Xi X, Wang H, et al. AaeAP1 and AaeAP2: Novel Antimicrobial Peptides from the Venom of the Scorpion, Androctonus aeneas: Structural Characterisation, Molecular Cloning of Biosynthetic Precursor-Encoding cDNAs and Engineering of Analogues with Enhanced Antimicrobial and Anticancer Activities. Toxins. 2015;7(2):219-37.
Sun Z-G, Li Z-N, Zhao L-H, Zhang J-M. Research Progress of Anti-breast Cancer Peptides. International Journal of Innovative Research in Medical Science. 2019;4(08):504-6.
Esmaeili MA, Abagheri-Mahabadi N, Hashempour H, Farhadpour M, Gruber CW, Ghassempour A. Viola plant cyclotide vigno 5 induces mitochondria-mediated apoptosis via cytochrome C release and caspases activation in cervical cancer cells. Fitoterapia. 2016;109:162-8.
Narayanan S. Sialic acid as a tumor marker. Annals of Clinical & Laboratory Science. 1994;24(4):376-84.
Manzo G, Scorciapino MA, Wadhwani P, Bürck J, Montaldo NP, Pintus M, et al. Enhanced amphiphilic profile of a short β-stranded peptide improves its antimicrobial activity. PloS one. 2015;10(1):e0116379.
Published
Abstract Display: 675 
PDF Downloads: 982 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.